GID BIO welcomes two new employees to the team as the newest of eight trial sites begin gearing up to enroll patients to participate in its pivotal trial: “Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis.” More sites will be added to our existing sites.
Committed to continuing to follow a stringent FDA approval process, we added Stephen Smith to the team. Stephen directs regulatory affairs and quality assurance, helping to ensure that all products comply with government standards and regulations.
Additionally, Amanda Lark joins as clinical research manager. She graduated from Colorado State University with a bachelor’s degree in biological sciences. Amanda has experience coordinating FDA-compliant Phase I – Phase IV oncology and ophthalmology trials. She will supervise trial sites across the nation and ensure compliance with FDA and ICH-GCP guidelines, standard operating procedures, and HIPAA requirements.
Both roles are integral to ensuring adherence to ethical practices and regulatory protocols.
For more information about the trial, visit clinicaltrials.gov.
Our cell therapy is not approved by the FDA for sale or use in the US.